{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026064","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.706316+00:00","generated_at":"2026-06-18T23:34:57.638304+00:00","sec_items":["2.02","9.01","5.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma upsizes buyback to $325M, cuts 17% staff, appoints new director","bullets":["Capital return program increased to $325M; $170M remaining; $155M repurchased to date.","Discontinuing research investments, reducing headcount by ~17%; inhaled JAK program to be partnered.","Q4 2022 YUPELRI net sales $19.5M (TBPH implied 35% share), up 27% YoY; total revenue $14.6M.","Appointed Susannah Gray to Board; William D. Young not standing for re-election; Board declassification proposal at May 2 AGM.","2023 guidance: R&D $35-45M, SG&A $45-55M; non-GAAP profit expected in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026064","json":"https://secwatch.observer/filing/0001104659-23-026064.json","markdown":"https://secwatch.observer/filing/0001104659-23-026064.md","text":"https://secwatch.observer/filing/0001104659-23-026064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/tm237863d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:34:57.638304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10d8676385","claim":"William D. Young departed as Director at Theravance Biopharma, Inc..","evidence_excerpt":"In addition, on February 26, 2023, William D. Young decided not to stand for re-election as a director at the Company’s next annual general meeting of shareholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"decided not to stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7231876c1","claim":"Susannah Gray was appointed as Director at Theravance Biopharma, Inc..","evidence_excerpt":"On February 26, 2023, Susannah Gray was appointed by the Board of Directors of Theravance Biopharma, Inc. (the “Company”) to serve as a Class II member of the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}